- Knight Therapeutics (OTC:KHTRF) has agreed to acquire Montevideo, Uruguay-based Biotoscana Investments S.A. (“Grupo Biotoscana”) for BRL 1,164M (C$369M).
- It will purchase a 51.21% stake from a controlling shareholder group for BRL 596M (C$189M) followed by a mandatory tender offer for the remaining 48.79% interest held by public investors (valued at C$190M if all shares are tendered).
- Grupo Biotoscana is a biopharmaceutical firm with operations in Argentina, Colombia, Chile, Ecuador and Peru and a presence in 10 countries throughout the region.
Source: Seeking Alpha
